Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-18
DOI
10.1186/s13045-022-01325-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
- (2022) Byoung Chul Cho et al. LANCET ONCOLOGY
- Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
- (2022) Charu Aggarwal et al. Journal for ImmunoTherapy of Cancer
- Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
- (2022) Ahmed Omar Kaseb et al. Lancet Gastroenterology & Hepatology
- SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
- (2022) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1
- (2021) Martin Reck et al. Journal of Thoracic Oncology
- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
- (2021) Paul Baas et al. LANCET
- VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
- (2021) Long Yuan et al. TRENDS IN IMMUNOLOGY
- Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
- (2021) Nathan D. Mathewson et al. CELL
- Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study
- (2021) Huiqiang Huang et al. Journal of Hematology & Oncology
- Understanding LAG-3 Signaling
- (2021) Luisa Chocarro et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CD38 in the Age of Covid-19: a Medical Perspective.
- (2021) Alberto Horenstein et al. PHYSIOLOGICAL REVIEWS
- Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
- (2021) Hidehito Horinouchi et al. CANCER SCIENCE
- An open‐label, non‐randomized, Phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma
- (2021) Astrid De Meulenaere et al. CTS-Clinical and Translational Science
- Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
- (2021) Hao Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia
- (2021) Anlai Wang et al. MOLECULAR CANCER THERAPEUTICS
- Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy
- (2021) Yi Sun et al. Science Translational Medicine
- PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
- (2021) Pottayil G. Sasikumar et al. Communications Biology
- A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
- (2021) Niharika B. Mettu et al. CLINICAL CANCER RESEARCH
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
- (2021) Thierry Facon et al. LANCET ONCOLOGY
- The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
- (2020) Alexandra Schnell et al. CELL RESEARCH
- VISTA: Coming of age as a multi‐lineage immune checkpoint
- (2020) M. A. ElTanbouly et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
- (2020) Mohamed A. ElTanbouly et al. SCIENCE
- CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint
- (2020) Miao Yu et al. Nature Communications
- CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection
- (2020) Erik Wennerberg et al. Cancer Immunology Research
- On the mechanism of anti-CD39 immune checkpoint therapy
- (2020) David Allard et al. Journal for ImmunoTherapy of Cancer
- A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
- (2020) Wenjie Zhai et al. Acta Pharmaceutica Sinica B
- Acquired Resistance to Immune Checkpoint Inhibitors
- (2020) Adam J. Schoenfeld et al. CANCER CELL
- PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
- (2020) Xiaozheng Xu et al. JOURNAL OF CELL BIOLOGY
- Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency
- (2020) Sujal Ghosh et al. BLOOD
- VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
- (2020) Xing Huang et al. Journal of Hematology & Oncology
- AHR is a Zika virus host factor and a candidate target for antiviral therapy
- (2020) Federico Giovannoni et al. NATURE NEUROSCIENCE
- Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
- (2020) Stephen M. Ansell et al. Blood Advances
- An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA
- (2020) Nishant Mehta et al. Scientific Reports
- A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma
- (2019) Sumanta K. Pal et al. CANCER
- A Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
- (2019) Gilles Salles et al. Clinical Lymphoma Myeloma & Leukemia
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
- (2019) David Cella et al. LANCET ONCOLOGY
- PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
- (2019) Yongshuai Jiang et al. Human Vaccines & Immunotherapeutics
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
- (2019) Branimir I. Sikic et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
- (2019) Hongwei Du et al. CANCER CELL
- The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration
- (2019) Stefano Barbera et al. Cell Communication and Signaling
- Intercellular Calcium Signaling Induced by ATP Potentiates Macrophage Phagocytosis
- (2019) Sara Zumerle et al. Cell Reports
- Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
- (2019) Ivan Perrot et al. Cell Reports
- Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
- (2019) H. K. Akturk et al. DIABETIC MEDICINE
- Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
- (2019) Martin Reck et al. EUROPEAN JOURNAL OF CANCER
- The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis
- (2019) Michelle A. Mintz et al. IMMUNITY
- CD27 Promotes CD4+ Effector T Cell Survival in Response to Tissue Self-Antigen
- (2019) Kelly A. Remedios et al. JOURNAL OF IMMUNOLOGY
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- CD73: an emerging checkpoint for cancer immunotherapy
- (2019) Siqi Chen et al. Immunotherapy
- Tumor neoantigens: from basic research to clinical applications
- (2019) Tao Jiang et al. Journal of Hematology & Oncology
- Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology
- (2019) Etienne Chatelut et al. CLINICAL PHARMACOKINETICS
- Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
- (2019) Xian-Yang Li et al. Cancer Discovery
- Immune checkpoint inhibitors win the 2018 Nobel Prize
- (2019) Pei-Wei Huang et al. Biomedical Journal
- Adenosine Metabolism: Emerging Concepts for Cancer Therapy
- (2019) Detlev Boison et al. CANCER CELL
- PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
- (2019) Yunlong Zhao et al. IMMUNITY
- CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
- (2019) Shi Yong Neo et al. JOURNAL OF CLINICAL INVESTIGATION
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- TIM-3 Regulates CD103 + Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
- (2018) Álvaro de Mingo Pulido et al. CANCER CELL
- Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer
- (2018) Lifeng Li et al. CANCER RESEARCH
- CD38-NAD + Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
- (2018) Shilpak Chatterjee et al. Cell Metabolism
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity
- (2018) Mohamad El-Zaatari et al. GASTROENTEROLOGY
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis
- (2018) Roberta Lugano et al. JOURNAL OF CLINICAL INVESTIGATION
- Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
- (2018) Todd A Triplett et al. NATURE BIOTECHNOLOGY
- Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways
- (2018) Xiaofan Guo et al. ONCOGENE
- CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma
- (2018) Yuk Pheel Park et al. ORAL ONCOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
- (2018) Charlotte E. Ariyan et al. Cancer Immunology Research
- Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome
- (2018) Véronique M. Braud et al. OncoImmunology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
- (2018) Xin Gao et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PD-1 Controls Follicular T Helper Cell Positioning and Function
- (2018) Jingwen Shi et al. IMMUNITY
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+Pools
- (2018) Jeffrey P. Chmielewski et al. MOLECULAR CANCER RESEARCH
- Induction and transcriptional regulation of the co-inhibitory gene module in T cells
- (2018) Norio Chihara et al. NATURE
- Immune Checkpoint Inhibitor Toxicity
- (2018) David J. Palmieri et al. Current Oncology Reports
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation
- (2018) Paras S. Minhas et al. NATURE IMMUNOLOGY
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- CD47 Protects Synapses from Excess Microglia-Mediated Pruning during Development
- (2018) Emily K. Lehrman et al. NEURON
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
- (2018) Sean H. Lim et al. Trials
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma
- (2018) Julija Hmeljak et al. Cancer Discovery
- Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling
- (2017) Meng Michelle Xu et al. IMMUNITY
- A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells
- (2017) Giada Mondanelli et al. IMMUNITY
- Immunoregulatory functions of VISTA
- (2017) Elizabeth C. Nowak et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
- (2017) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways
- (2017) F Xia et al. LEUKEMIA
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases
- (2017) Kathleen A. Hershberger et al. Nature Reviews Nephrology
- Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases
- (2017) Michael Croft et al. Nature Reviews Rheumatology
- Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
- (2017) Sharareh Gholamin et al. Science Translational Medicine
- Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
- (2016) Xiaohong Wang et al. CANCER RESEARCH
- Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers
- (2016) Qiong J. Wang et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
- (2016) Frank A. Schildberg et al. IMMUNITY
- CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
- (2016) Carsten Riether et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases
- (2016) Bruce N. Cronstein et al. Nature Reviews Rheumatology
- Pembrolizumab (Keytruda)
- (2016) Gerry Kwok et al. Human Vaccines & Immunotherapeutics
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
- (2016) Noha Abdel-Wahab et al. PLoS One
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia
- (2015) Masayuki Iwasaki et al. Cell Stem Cell
- pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27+ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma
- (2015) M. Ruf et al. CLINICAL CANCER RESEARCH
- TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity
- (2015) Jennifer D Stone et al. CURRENT OPINION IN IMMUNOLOGY
- Splenic Dendritic Cells Survey Red Blood Cells for Missing Self-CD47 to Trigger Adaptive Immune Responses
- (2015) Tangsheng Yi et al. IMMUNITY
- Mechanistic Assessment of PD-1H Coinhibitory Receptor–Induced T Cell Tolerance to Allogeneic Antigens
- (2015) Dallas B. Flies et al. JOURNAL OF IMMUNOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD70: An emerging target in cancer immunotherapy
- (2015) J. Jacobs et al. PHARMACOLOGY & THERAPEUTICS
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
- (2014) Dallas B. Flies et al. JOURNAL OF CLINICAL INVESTIGATION
- Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
- (2014) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells
- (2013) Joanne Y. H. Lim et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Novel Recombinant Human B7-H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses
- (2013) D. Dangaj et al. CANCER RESEARCH
- The CD70-CD27 Axis, a New Brake in the T Helper 17 Cell Response
- (2013) Xiaohu Wang et al. IMMUNITY
- Adenosine receptors as drug targets — what are the challenges?
- (2013) Jiang-Fan Chen et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies
- (2011) D. R. Shaffer et al. BLOOD
- Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway
- (2011) Y. Sakoda et al. BLOOD
- DNA Viruses (CMV, EBV, and the Herpesviruses)
- (2011) Martin Zamora SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- TNF superfamily in inflammatory disease: translating basic insights
- (2011) Michael Croft et al. TRENDS IN IMMUNOLOGY
- Plasmacytoid dendritic cells regulate B-cell growth and differentiation via CD70
- (2010) J. Shaw et al. BLOOD
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- B7-H4 mediates inhibition of T cell responses by activated murine hepatic stellate cells
- (2010) Raghavan Chinnadurai et al. HEPATOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
- (2010) M. P. Chao et al. Science Translational Medicine
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Fine tuning the immune response through B7-H3 and B7-H4
- (2009) Kyung H. Yi et al. IMMUNOLOGICAL REVIEWS
- Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology
- (2009) Martijn A. Nolte et al. IMMUNOLOGICAL REVIEWS
- Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
- (2008) J. A. McEarchern et al. CLINICAL CANCER RESEARCH
- Regulated Catalysis of Extracellular Nucleotides by Vascular CD39/ENTPD1 Is Required for Liver Regeneration
- (2008) Guido Beldi et al. GASTROENTEROLOGY
- Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells
- (2008) Richard K. Tsai et al. JOURNAL OF CELL BIOLOGY
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started